
Latest News
Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture
April 3, 2024
Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.
EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.
Click here to visit AMGEN Canada and read the full release.
To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/
OC MAKES THE NEWS – RECENT ITEMS
Osteoporosis Canada Becomes HealthPartners Member
May 16, 2025
Latest News Osteoporosis Canada Becomes HealthPartners Member May 16, 2025 In March 2025 it was announced that Osteoporosis Canada was one of three new charities to join the membership of […]
Dr. Lora Giangregorio Named Canada Research Chair
March 19, 2025
Latest News Dr. Lora Giangregorio Named Canada Research Chair March 19, 2025 The University of Waterloo, Kinesiology and Health Sciences Professor Lora Giangregorio has been awarded a Tier 1 Canada […]
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Latest News Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario February 20, 2025 Apo-Teriparatide Injection ™ is a generic alternative to Forteo®. Osteoporosis pharmacologic therapies are classified […]